ClinicalTrials.gg

Program

TYK2 Inhibitor

Its studies are mostly in Psoriasis, led by Usynova Pharmaceuticals.

Furthest: no phase, since Nov 14, 20251 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Usynova Pharmaceuticals11 open or runningno phasesince Nov 14, 2025Nov 14, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 14, 2025First study: no phase study in Plaque PsoriasisFirst studyNCT07234591 · 140 planned · China

TargetBeta

TYK2 →read by rule
“Any agent that inhibits the non-receptor tyrosine-protein kinase TYK2 (tyrosine kinase 2).”NCIt, by rule

Other programs on TYK2

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
deucravacitinibruleBristol-Myers Squibbphase 460
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
brepocitinibrulePfizerphase 325
delgocitinibruleLEO Pharmaphase 321
D-2570ruleInventisBiophase 313
HS-10374Hansoh Pharmaceutical Groupphase 36
TQH3906Sino Biopharmaceuticalphase 36
FXS5626Fosun Pharmaphase 33

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07234591Plaque Psoriasis · China–RecruitingApr 30, 2026140

How it is read

Names in the registry

  • “Tyk2 inhibitor”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.